Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Butyrate Clear all
Recruiting Not applicable Interventional

Precision Medicine and Physical Function

NCT05877846
View directory record Official record
Conditions
Frailty, Weakness, Muscle, Multiple Chronic Conditions
Interventions
Beta-hydroxymethyl butyrate supplement, Vitamin D supplement, Matching Beta-hydroxymethyl butyrate supplement without Vitamin D
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 23, 2026, 11:50 AM EDT
Recruiting Phase 3 Interventional

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Not applicable Interventional Results available

The Effect of Neurontin on Pain Management in the Acutely Burned Patient

NCT01265056
View directory record Official record
Conditions
Pain, Burn Injury
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Lucy A Wibbenmeyer
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 23, 2026, 11:50 AM EDT
Not yet recruiting Phase 1 Interventional

Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy

NCT07790575
View directory record Official record
Conditions
Cytopenia
Interventions
AZD0120, Bendamustin
Drug
Lead sponsor
Saurabh Dahiya
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 11:50 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids

NCT06882772
View directory record Official record
Conditions
Congenital Heart Disease (CHD)
Interventions
2 mL SunButyrate-TG, Placebo, 4 mL SunButyrate-TG
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
1 Month to 3 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Phase 4 Interventional Results available

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

NCT03817853
View directory record Official record
Conditions
Advanced Follicular Lymphoma
Interventions
Obinutuzumab, Bendamustine, Cyclophosphamide, Doxorubicin, Prednisone/Prednisolone/Methylprednisolone, Vincristine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Boulder, Colorado • Bethesda, Maryland • Florham Park, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 23, 2026, 11:50 AM EDT
Withdrawn Phase 2 Interventional

A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

NCT01423539
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
bendamustine, navitoclax, rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Fountain Valley, California • Hudson, Florida • Lawrenceville, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Phase 3 Interventional

An Open-Label Trial of Pregabalin in Patients With Fibromyalgia

NCT00151528
View directory record Official record
Conditions
Fibromyalgia
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

NCT03574792
View directory record Official record
Conditions
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Gabapentin, Methadone, Oxycodone, Quality-of-Life Assessment, Questionnaire Administration, Venlafaxine, Venlafaxine Hydrochloride Extended Release
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

Gabapentin for Alcohol Relapse Prevention

NCT02349477
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Withdrawal
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Phase 2 Interventional

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

NCT00069758
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
SDX-105
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Palm Springs, California • Vista, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 23, 2026, 11:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

NCT05624554
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab, Truxima, Ruxience, Riabni
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
4
States / cities
Springdale, Arkansas • Clermont, Florida • Hattiesburg, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Phase 3 Interventional

Trial of Efficacy and Safety of Pregabalin in Subjects With Neuropathic Pain Associated With Lumbo-Sacral Radiculopathy

NCT00159705
View directory record Official record
Conditions
Radiculopathy
Interventions
pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Phoenix, Arizona • Denver, Colorado • Plantation, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 23, 2026, 11:50 AM EDT
Recruiting Phase 2 Interventional

Study of Novel Therapeutics for Acute Remedy of Colitis

NCT06420492
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Interventions
BRS201
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Not applicable Interventional Results available

Treating Alcohol Withdrawal With Oral Baclofen

NCT00597701
View directory record Official record
Conditions
Alcohol Withdrawal Delirium
Interventions
Baclofen, Placebo, Lorazepam
Drug
Lead sponsor
Essentia Health
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Phase 4 Interventional

Feasibility of Early Gabapentin as an Intervention for Neurorecovery

NCT05302999
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Phase 4 Interventional Results available

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

NCT00351611
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Lyrica (pregabalin), placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
103
States / cities
Mobile, Alabama • Northport, Alabama • Tuscaloosa, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin

NCT00187707
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

NCT00636792
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
VELCADE, Bendamustine, Rituximab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bismarck, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 23, 2026, 11:50 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Gabapentin Premedication to Reduce Postoperative Pain for Pediatric Tonsillectomy

NCT03625011
View directory record Official record
Conditions
Tonsillitis, Tonsillectomy
Interventions
Gabapentin
Drug
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
3 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 23, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo

NCT00352651
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
Pregabalin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 23, 2026, 11:50 AM EDT
Terminated Not applicable Interventional

Measurements From Stool to Support Dietary Change

NCT04037306
View directory record Official record
Conditions
Diet Habit, Feeding Behavior, Behavior, Health
Interventions
Butyrate Feedback, Fiber Feedback
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 23, 2026, 11:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Gabapentin for Abstinence Initiation in Alcohol Dependence

NCT01141049
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 23, 2026, 11:50 AM EDT
Terminated Phase 3 Interventional

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

NCT00145431
View directory record Official record
Conditions
Hyperlipoproteinemia Type III
Interventions
torcetrapib/atorvastatin, atorvastatin, fenofibrate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Anaheim, California • Huntington Beach, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 23, 2026, 11:50 AM EDT